Skip to main content

Table 2 Tumor response in evaluable patients according to RECIST

From: A phase I/II study of weekly nab-paclitaxel plus cisplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer

 

n = 22

Objective response

 Complete response, n (%)

0 (0.0)

 Partial response, n (%)

13 (59.1)

 Stable disease, n (%)

6 (27.3)

 Progressive disease, n (%)

3 (13.6)

 Not evaluable, n (%)

0 (0.0)

Objective response rate (%)

13 (59.1)

 90% CI, %

41.8–74.4

Disease control rate (%)

19 (86.4)

 95% CI, %

66.7–95.3